Atlas Trials

A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

Clinical trial NCT07178717 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07178717
Sponsor
Vall d'Hebron Institute of Oncology
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Colo-rectal Cancer
Start date
2025-10-01
Primary completion
2028-02-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.